MedTrace Logo

Study of CRx-191 to Assess Activity in Plaque Psoriasis

NCT00557739 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-09-25

No results posted yet for this study

Summary

CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor- alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of psoriasis.

This clinical trial will assess the effectiveness of CRx-191 in reducing the psoriatic infiltrate band thickness as measured by transdermal ultrasound. All subjects will receive all treatments in separate test fields, with intra-individual comparison of the treatments.

Conditions

Interventions

DRUG

mometasone furoate

Topical 0.1% mometasone furoate

DRUG

nortriptyline HCl

Topical 0.05% or 0.1% nortriptyline HCl

DRUG

Vehicle (placebo)

Topical placebo

Sponsors & Collaborators

  • Bioskin GmbH

    collaborator INDUSTRY

  • Zalicus

    lead INDUSTRY

Principal Investigators

  • Johannes Gassmueller, M.D. · Bioskin GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00557739 on ClinicalTrials.gov